Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
InnoCan Pharma ( (TSE:INNO) ) has issued an announcement.
Innocan Pharma reported that its liposomal synthetic cannabidiol (LPT-CBD) injection showed clinically meaningful pain relief versus placebo in a randomized, blinded crossover trial in dogs with naturally occurring osteoarthritis. The peer-reviewed study in Frontiers in Veterinary Science found significant improvements in behavior, function, lameness, and pain scores, with all treated dogs showing functional gains and only minor, self-limiting adverse events.
The trial demonstrated that a single subcutaneous dose of LPT-CBD produced sustained plasma CBD levels and corresponding pain relief for up to four weeks, supporting its positioning as a long-acting non-opioid pain management option in veterinary medicine. Management highlighted that these data, along with prior efficacy studies in multiple animal species, underpin ongoing discussions with U.S. regulators to advance LPT-CBD in both veterinary and human analgesia markets, potentially broadening Innocan’s commercial and clinical footprint.
The most recent analyst rating on (TSE:INNO) stock is a Hold with a C$8.50 price target. To see the full list of analyst forecasts on InnoCan Pharma stock, see the TSE:INNO Stock Forecast page.
Spark’s Take on TSE:INNO Stock
According to Spark, TipRanks’ AI Analyst, TSE:INNO is a Neutral.
The score is weighed down primarily by weak financial performance (ongoing losses and deteriorating cash flow despite strong gross margins and low leverage). Technicals also remain soft with negative MACD and price below key longer-term moving averages. Valuation is only mildly supportive because the negative P/E reflects lack of profitability and no dividend data is available.
To see Spark’s full report on TSE:INNO stock, click here.
More about InnoCan Pharma
Innocan Pharma is a pharmaceutical and wellness innovator focused on cannabinoid-based therapies and consumer products. Its core pharmaceutical platform is a CBD-loaded liposomal drug delivery system designed for precise dosing and prolonged, controlled release of synthetic CBD for non-opioid pain management, while its wellness arm markets self-care and beauty products via a majority-owned online-focused subsidiary.
YTD Price Performance: -5.67%
Average Trading Volume: 1,540
Technical Sentiment Signal: Sell
Current Market Cap: C$28.43M
For detailed information about INNO stock, go to TipRanks’ Stock Analysis page.